Search Results

You are looking at 41 - 50 of 117 items for :

  • "consolidation therapy" x
  • Refine by Access: All x
Clear All
Full access

Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Philip L. McCarthy

. 12 Cavo M Tacchetti P Patriarca F . Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly

Full access

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale Bixby, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Thomas W. LeBlanc, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Margaret R. O’Donnell, Rebecca Olin, Deniz Peker, Alexander Perl, Daniel A. Pollyea, Keith Pratz, Thomas Prebet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew Wieduwilt, Kristina M. Gregory, OCN, Lydia Hammond, and Ndiya Ogba

% CI, 31.5–not reached [NR]) in the midostaurin group compared with 25.6 months (95% CI, 18.6–42.9) in the placebo group ( P =.009). 32 Patients who received midostaurin with standard induction and consolidation therapy experienced significant

Full access

Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective

Ranee Mehra, Candice Yong, Brian Seal, Marjolijn van Keep, Angie Raad, and Yiduo Zhang

, durvalumab remained cost-effective, with an ICER of $79,609 per QALY. Therefore, our analysis builds on the work of Criss et al 35 to provide a more robust estimate of the costs associated with durvalumab consolidation therapy, given current clinical

Full access

Therapeutic Advances in Relapsed or Refractory Multiple Myeloma

Kenneth C. Anderson

-thalidomide-dexamethasone compared with thalidomide-dexamethasone as consolidation therapy following double autologous transplantation for multiple myeloma: results of a qualitative and quantitative analysis . Haematologica 2011 ; 96 ( s1 ): S96 . Abstract P224 . 2

Full access

Chemotherapy in the Management of Osteosarcoma and Ewing's Sarcoma

Scott M. Schuetze

the Children's Oncology Group . J Clin Oncol 2006 ; 24 : 152 – 159 . 56. Meyers PA Krailo MD Ladanyi M . High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high

Full access

Fixed-Duration Versus Until Disease Progression: How Long Should Initial Treatment of Multiple Myeloma Last?

Yvonne A. Efebera and Nina Shah

group and Dana-Farber Cancer Institute. 2 In this study, investigators randomly assigned patients with MM to receive either (1) induction therapy with 3 cycles of lenalidomide/bortezomib/dexamethasone (RVD) and then consolidation therapy with either 5

Full access

Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia

Martin Tallman

be given for secondary AML or AML with MRC. GO can be given to patients who are CD33-positive with 7+3 induction and consolidation therapy on days 1, 4, and 7 or as a single agent days 1 and 8. The 2018 NCCN Guidelines for AML state that after

Full access

National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non–Small Cell Lung Cancer

Stephen R. Grant, Benjamin D. Smith, Lauren E. Colbert, Qunyh-Nhu Nguyen, James B. Yu, Steven H. Lin, and Aileen B. Chen

consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study . J Clin Oncol 2019 ; 37 : 1558 – 1565 . 17. Palma DA

Full access

Advances in Acute Myeloid Leukemia Management: Focus on Secondary Disease and Older Patients

Presented by: Daniel A. Pollyea

CPX-351 must also be able to tolerate intensive induction chemotherapy. Ongoing research is evaluating whether CPX-351 can be given on an outpatient basis as induction or consolidation therapy. When giving glasdegib, he warned of the potential for

Full access

Management of Newly Diagnosed Multiple Myeloma Based on Risk Stratification

Presented by: Natalie S. Callander

- versus 3-drug induction regimen. 4 This trend seemed to correlate with the 4-year PFS rates (87.2% vs 70.0%, respectively). In the MASTER trial, MRD assessments guided the continuation or cessation of posttransplant consolidation therapy. 5 This